Results 81 to 90 of about 2,105 (188)

Matrix Metalloproteinase Inhibition in Melanoma

open access: yesExperimental Dermatology, Volume 35, Issue 1, January 2026.
ABSTRACT Matrix metalloproteinases (MMPs) are involved in the degradation of the extracellular matrix (ECM) and are found to participate in all stages of tumour progression including modifying signalling pathways, regulating cytokines and promoting tumour growth, particularly by inducing angiogenesis and facilitating cancer spread.
Ellie Zhang   +2 more
wiley   +1 more source

Delivery and/or retention of Evans blue dye or frontline TB drugs in infected animals treated with Marimastat.

open access: yes, 2018
(A): Mtb infected mice treated with or without Marimastat were injected intravenously with Evans blue dye before euthanization. Retention of Evans blue dye within the lung of infected mice treated with or without Marimastat. Data represented mean ± SD. **
Veronique Dartois (2283115)   +12 more
core   +1 more source

TACE inhibition: a promising therapeutic intervention against AATF‐mediated steatohepatitis to hepatocarcinogenesis

open access: yesMolecular Oncology
Metabolic dysfunction‐associated steatohepatitis‐driven hepatocellular carcinoma (MASH‐HCC) is a global clinical challenge for which there is a limited understanding of disease pathogenesis and a subsequent lack of therapeutic interventions.
Akshatha N. Srinivas   +6 more
doaj   +1 more source

Macrophage elastase (MMP-12): a pro-inflammatory mediator?

open access: yesMemorias do Instituto Oswaldo Cruz, 2005
As many metalloproteinases (MMPs), macrophage elastase (MMP-12) is able to degrade extracellular matrix components such as elastin and is involved in tissue remodeling processes.
Soazig Nénan   +3 more
doaj   +1 more source

Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer

open access: yesBritish Journal of Cancer, 2004
Marimastat, low molecular weight heparins and captopril have antiangiogenic activity in vitro and in animal models. We studied the safety and efficacy of the combination of these drugs in patients with advanced cancer. In all, 50 patients were enrolled. Captopril was given orally at a dose of 50 mg bd daily.
Jones, P H   +12 more
openaire   +2 more sources

Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma

open access: yesSmall, Volume 21, Issue 49, December 10, 2025.
This graphical abstract illustrates nanosystems used for targeted drug delivery into tuberculosis granulomas. It shows how targeting is influenced by size, pH, redox sensitivity, and surface charge. Various nanoparticles are incorporated with drugs to enhance penetration, stability, and release.
Shreya Ranjith Singh   +3 more
wiley   +1 more source

System biology approach to identify the novel biomarkers in glioblastoma multiforme tumors by using computational analysis

open access: yesFrontiers in Pharmacology
Introduction: The most common primary brain tumor in adults is glioblastoma multiforme (GBM), accounting for 45.2% of all cases. The characteristics of GBM, a highly aggressive brain tumor, include rapid cell division and a propensity for necrosis ...
Safar M. Alqahtani   +8 more
doaj   +1 more source

EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression

open access: yesBMC Cancer, 2012
Backgrounds An elevated level of EMMPRIN in cancer tissues have been correlated with tumor invasion in numerous cancers including oral cavity and larynx.
Lescaille Géraldine   +9 more
doaj   +1 more source

Marimastat reduces necroinflammatory injury following a single dose of carbon tetrachloride (CCl4) via a TNF-dependent pathway.

open access: yes, 2013
Liver sections from Marimastat-treated animals that had been administered a single dose of CCl4 revealed decreased necroinflammatory injury after 24 h (A). Marimastat treatment resulted in a 57% decrease of serum ALT levels (B). Liver sections from Mmp9−/
Hau D. Le (343378)   +7 more
core   +1 more source

Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling. [PDF]

open access: yesMol Cell Proteomics
21 páginas, 8 figuras.New treatments that circumvent the pitfalls of traditional antivenom therapies are critical to address the problem of snakebite globally.
Smith CF   +15 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy